Article PDF
Use our pre-submission checklist
Avoid common mistakes on your manuscript.
About this article
Cite this article
Disponible en ambulatoire, HUMIRA® (adalimumab), le 1er anti-TNFα 100 % humain recombinant permet une rémission rapide et durable de la maladie de Crohn. Acta Endosc 38, 201–203 (2008). https://doi.org/10.1007/BF02961967
Issue Date:
DOI: https://doi.org/10.1007/BF02961967